Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing Technologies to LabCorp®

  Illumina Signs Master Supply Agreement to Provide Next-Generation Sequencing
  Technologies to LabCorp®

Business Wire

SAN DIEGO -- January 21, 2014

Illumina, Inc. (NASDAQ:ILMN) today announced it has entered into a multi-year
supply agreement with Laboratory Corporation of America® Holdings (LabCorp®)
(NYSE: LH). The agreement gives LabCorp expanded rights to use Illumina
next-generation sequencing (NGS) and microarray equipment and supplies to
develop, validate and introduce laboratory-developed tests to clinicians in
the United States and Canada.

Under the terms of the agreement, LabCorp will be able to purchase a broader
range of Illumina products for the development of new diagnostic tools in
multiple specialties, including genetic testing, oncology, transplant medicine
and forensics, in addition to other applications. LabCorp is currently using
the technology in connection with new human leukocyte antigen (HLA) tests that
it plans to introduce this year.

“The Illumina next-generation sequencing platform gives LabCorp the
flexibility to develop a wide range of molecular tests,” said Dr. Mark
Brecher, LabCorp’s Chief Medical Officer. “The HLA typing assays we are
developing on Illumina’s family of NGS platforms will provide physicians with
the ability to more accurately match bone marrow donors to recipients.”

“We are excited to support LabCorp’s ability to offer more NGS-based tests
such as its HLA offering,” said Nicholas J. Naclerio, Illumina’s Senior Vice
President of Corporate & Venture Development. “Illumina is committed to making
NGS broadly available for clinical laboratory testing, and this agreement with
LabCorp significantly expands the number of clinicians and patients who will
have access to improved diagnostic tools and information.”

AboutIllumina

Illumina(www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.